{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:05:11Z","timestamp":1787069111766,"version":"build-2736575974"},"reference-count":157,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2022,4,3]]},"DOI":"10.1080\/14728214.2022.2091131","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T02:38:00Z","timestamp":1655519880000},"page":"151-167","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":31,"title":["Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II &amp; III trials"],"prefix":"10.1080","volume":"27","author":[{"given":"Katharina A.","family":"Mayer","sequence":"first","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-7977","authenticated-orcid":false,"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Doberer","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg A.","family":"B\u00f6hmig","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1802677"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14320"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003274"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14337"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03840.x"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020081215"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2003.00072.x"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14600"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15898"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017030287"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003095"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2022.10140"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2012.212"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2015.02.004"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13115"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.11.029"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0b013e3283636e55"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32473-5"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13113-5"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020111558"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.816555"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002049"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03525.x"},{"issue":"3","key":"cit0024","first-page":"S1","volume":"9","author":"Kidney Disease: Improving Global Outcomes Transplant Work G","year":"2009","journal-title":"Am J Transplant"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198108000-00019"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1159\/000183067"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198305000-00006"},{"key":"cit0028","first-page":"698","volume":"31","author":"Bonomini V","year":"1985","journal-title":"Trans Am Soc Artif Intern Organs"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01613.x"},{"key":"cit0030","unstructured":"GODT. Executive Summary of 2020 Activity Data. WHO-ONT. 2021. [cited 2022 Feb 25]. Available from: http:\/\/www.transplant-observatory.org\/2020-international-activities-report\/"},{"key":"cit0031","unstructured":"USRDS. 2021 Annual Report. USRDS Coordinating Center. 2021. [cited 2022 Feb 25]. Available from: https:\/\/adr.usrds.org\/2021\/end-stage-renal-disease\/1-incidence-prevalence-patient-characteristics-and-treatment-modalities"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2014530"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2002.21015.x"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04670514"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1964267"},{"key":"cit0036","unstructured":"NCT03744910. Clazakizumab for the treatment of chronic active antibody mediated rejection in kidney transplant recipients (IMAGINE). Bethesda (MD): U.S. National Library of Medicine; 2018 [updated 2022 Mar 3; cited 2022 Feb 22]. updated 2022 Mar 3: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03744910"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16474"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13436"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16828"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501929"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132011"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612567"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002924"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003496"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16754"},{"key":"cit0046","unstructured":"NCT03897205. An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients. Bethesda (MD): U.S. National Library of Medicine; 2019 [updated 2021 Dec 8; cited 2022 Feb 22]. updated 2021 Dec 8: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03897205"},{"key":"cit0047","unstructured":"NCT04711850. An long-term follow-up trial of kidney Tx patients treated with imlifidase or pe after an AMR. Bethesda (MD): U.S. National Library of Medicine; 2021 [updated 2021 Dec 9; cited 2022 Feb 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04711850"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2018.10.004"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002267"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14256"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14528"},{"key":"cit0052","unstructured":"NCT05156710. BIVV020 in prevention and treatment of Antibody-mediated Rejection (AMR). Bethesda (MD): U.S. National Library of Medicine; 2021 [updated 2022 Feb 17; cited 2022 Feb 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05156710"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03757.x"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13168"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15364"},{"key":"cit0056","unstructured":"NCT01895127. Efficacy and safety of eculizumab for treatment of antibody-mediated rejection following renal transplantation. Bethesda (MD): U.S. National Library of Medicine; 2013 [updated Sept 21, 2017; cited Feb 22, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01895127"},{"key":"cit0057","unstructured":"NCT01327573. Eculizumab therapy for chronic complement-mediated injury in kidney transplantation. Bethesda (MD): U.S. National Library of Medicine; 2011 [updated Aug 12, 2019; cited Feb 20, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01327573"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14001"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003754"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000592"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14767"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13663"},{"key":"cit0063","unstructured":"NCT01147302. A pilot study to evaluate the use of c1 esterase inhibitor (human) in patients with acute antibody-mediated rejection. Bethesda (MD): U.S. National Library of Medicine; 2010 [updated Jun 11, 2021; cited Feb 20, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01147302"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13871"},{"key":"cit0065","unstructured":"NCT02547220. A multicenter study to evaluate the efficacy and safety of cinryze\u00ae for the treatment of acute antibody-mediated rejection in participants with kidney transplant. Bethesda (MD): U.S. National Library of Medicine; 2015 [updated 2020 Jul 13; cited 2022 Feb 22]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02547220"},{"key":"cit0066","unstructured":"NCT03221842. Efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care for the treatment of refractory antibody mediated rejection (AMR) in adult renal transplant recipients. Bethesda (MD): U.S. National Library of Medicine; 2017 [updated Jan 18, 2022; cited Feb 22, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03221842"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft502"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1159\/000506504"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12544"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14721"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021050628"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14738"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003278"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00454.x"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000261113.30757.d1"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181a6bac5"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2012.01544.x"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12535"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02411.x"},{"key":"cit0080","unstructured":"NCT01066689. Impact of treatment with rituximab on the progression of humoral acute rejection after renal transplantation (RITUX-ERAH). Bethesda (MD): U.S. National Library of Medicine; 2010 [updated Feb 10, 2010; cited Feb 20, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01066689"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000958"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13613"},{"key":"cit0083","unstructured":"2010-023746-67. Treatment with intravenous immunoglobulins and rituximab in renal transplant recipients with chronic humoral rejection: a multicentre, prospective, randomized, placebo-controlled study. Amsterdam Netherlands: EU Clinical Trials Register; 2014 [updated Dec 4, 2021; cited Feb 25, 2022]. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2010-023746-67"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14520"},{"key":"cit0085","unstructured":"NCT00476164. Study of rituximab to treat chronic renal transplant rejection (RituxiCAN-C4). Bethesda (MD): U.S. National Library of Medicine; 2007 [Cited 2020 Mar 5] Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00476164"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00079"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00502.x"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0808481"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000515"},{"key":"cit0090","unstructured":"NCT03994783. transplant antibody-mediated rejection: guiding effective treatments (TAR:GET-1). Bethesda (MD): U.S. National Library of Medicine; 2019 [updated Apr 1, 2021; cited Feb 25, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03994783"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017070749"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017121296"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003249"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14228"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000000988"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13908"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.790547"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16391"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16459"},{"key":"cit0100","unstructured":"NCT03444103. A pilot trial of clazakizumab in late ABMR. Bethesda (MD): U.S. National Library of Medicine; 2018 [updated Sept 9, 2020; cited Feb 25, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03444103"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020071106"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15913"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.01.1074"},{"key":"cit0104","unstructured":"NCT04561986. TocIlizumab in chronic antibody-mediated rejection in kidney transplant recipients (INTERCEPT). Bethesda (MD): U.S. National Library of Medicine; 2020 [updated Feb 17, 2022; cited Feb 25, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04561986"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.02039.x"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.502"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318190af83"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181fdd9b0"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318218e901"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr465"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2014.5892"},{"key":"cit0112","unstructured":"NCT01873157. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT). Bethesda (MD): U.S. National Library of Medicine; 2013 [updated Mar 23, 2017; cited Feb 22, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01873157"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-15-107"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017070818"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016070727"},{"key":"cit0116","unstructured":"NCT02201576. Bortezomib in rejection of kidney transplants (TRIBUTE). Bethesda (MD): U.S. National Library of Medicine; 2014 [updated Sept 16, 2020; cited Feb 22, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02201576"},{"key":"cit0117","unstructured":"NCT03737136. Comparison between bortezomib and rituximab plus plasmapheresis in AMR. Bethesda (MD): U.S. National Library of Medicine; 2018 [updated Jan 28, 2022; cited Feb 22, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03737136"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15067"},{"key":"cit0119","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019030304"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0000000000000832"},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.688301"},{"key":"cit0122","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-740944"},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023325"},{"key":"cit0124","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018121254"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.1159\/000503951"},{"key":"cit0126","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003247"},{"key":"cit0127","unstructured":"NCT05021484. Felzartamab in late antibody-mediated rejection. Bethesda (MD): U.S. National Library of Medicine; 2021 [updated Aug 25, 2021; cited Feb 25, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05021484"},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06198-9"},{"key":"cit0129","unstructured":"NCT04610320. Daratumumab-SC for highly sensitized patients awaiting heart transplantation. Bethesda (MD): U.S. National Library of Medicine; 2020 [updated September 21, 2021; cited Feb 25, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04610320"},{"key":"cit0130","unstructured":"NCT04204980. Desensitization in kidney allograft using daratumumab (DARDAR). Bethesda (MD): U.S. National Library of Medicine; 2019 [updated May 21, 2020; cited Feb 25, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04204980"},{"key":"cit0131","unstructured":"NCT04294459. Safety, pharmacokinetics, and preliminary efficacy of isatuximab in patients awaiting kidney transplantation. Bethesda (MD): U.S. National Library of Medicine; 2020 [updated Jan 24, 2022; cited Feb 25, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04294459"},{"key":"cit0132","unstructured":"NCT04827979. Daratumumab and belatacept for desensitization (ATTAIN). Bethesda (MD): U.S. National Library of Medicine; 2021 [updated Jan 28, 2022; cited Feb 25, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04827979"},{"key":"cit0133","unstructured":"NCT05145296. the safety\/efficacy of daratumumab with belatacept in highly HLA-sensitized patients awaiting kidney transplantation (COMBAT). Bethesda (MD): U.S. National Library of Medicine; 2021 [updated Dec 6, 2021; cited 2021; cited Feb 25, 2022 Dec 6, 2021; cited Feb 6, 2021; cited Feb 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05145296"},{"key":"cit0134","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001617"},{"key":"cit0135","unstructured":"NCT01630538. cyclophosphamide therapy for refractory antibody-mediated rejection (AMR) in kidney transplants. Bethesda (MD): U.S. National Library of Medicine; 2012 [updated Apr 19, 2018; cited Feb 22, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01630538"},{"key":"cit0136","unstructured":"NCT02546492. Treatment of chronic antibody-mediated rejection in kidney transplant with acthar (TGActhar). Bethesda (MD): U.S. National Library of Medicine; 2015 [updated Feb 10, 2022; cited Feb 22, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02546492"},{"key":"cit0137","unstructured":"NCT03991780. Fostamatinib in the treatment of chronic active antibody mediated rejection (FOSTAMR). Bethesda (MD): U.S. National Library of Medicine; 2019 [updated Oct 4, 2021; cited Feb 22, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03991780"},{"key":"cit0138","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-06413-2"},{"key":"cit0139","doi-asserted-by":"publisher","DOI":"10.1159\/000508170"},{"key":"cit0140","doi-asserted-by":"publisher","DOI":"10.1111\/tri.14006"},{"key":"cit0141","first-page":"6","volume":"10","author":"Gregorini M","year":"2021","journal-title":"Biology (Basel)"},{"key":"cit0142","unstructured":"NCT04870437. Impact of extracorporeal phototherapy (ECP) on auxiliary follicular T-lymphocytes and circulating B-lymphocytes during chronic antibody-mediated rejection in kidney transplantation. (IPECAM). Bethesda (MD): U.S. National Library of Medicine; 2021 [updated May 3, 2021; cited Feb 25, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04870437"},{"key":"cit0143","unstructured":"NCT03585855. Mesenchymal stem cell transplantation in the treatment of chronic antibody mediated kidney graft rejection (ABMR). Bethesda (MD): U.S. National Library of Medicine; 2018 [updated Jul 25, 2019; cited Feb 22, 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03585855"},{"key":"cit0144","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.708744"},{"key":"cit0145","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14979"},{"key":"cit0146","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13813"},{"key":"cit0147","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4923"},{"key":"cit0148","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2022.10137"},{"key":"cit0149","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13954"},{"key":"cit0150","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001292"},{"key":"cit0151","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13778"},{"issue":"10","key":"cit0152","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1002\/art.39249","volume":"67","author":"Weinblatt ME","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"cit0153","doi-asserted-by":"publisher","DOI":"10.1002\/art.39700"},{"key":"cit0154","doi-asserted-by":"publisher","DOI":"10.1007\/DCR.0b013e3181f5643c"},{"key":"cit0155","doi-asserted-by":"publisher","DOI":"10.1002\/art.39761"},{"key":"cit0156","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0000000000000754"},{"key":"cit0157","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1728796"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2022.2091131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T08:56:47Z","timestamp":1661417807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2022.2091131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,3]]},"references-count":157,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4,3]]}},"alternative-id":["10.1080\/14728214.2022.2091131"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2022.2091131","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}